Influence of a latent period in QALY anaylsis: Pilot study of intrathecal drug delivery systems for chronic non-malignant pain

British Journal of Neurosurgery

Volumn 25, Issue 3, 2011, Pages 401-406

  Biggs, Simon A ^a   Duarte, Rui V ^a,b   Raphael, Jon H ^a,b   Ashford, Robert L ^b  

^a DUDLEY GROUP OF HOSPITALS NHS TRUST   (United Kingdom)

^b BIRMINGHAM CITY UNIVERSITY   (United Kingdom)

Author keywords

Chronic non malignant pain; cost effectiveness; intrathecal drug delivery systems (IDDS); latent period; QALY analysis

Indexed keywords

ADULT; AGED; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; FEMALE; HEALTH CARE COST; HUMAN; IMPLANT; INTRATHECAL DRUG DELIVERY SYSTEM; LATENT PERIOD; LONGITUDINAL STUDY; MALE; PATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DRUG DELIVERY SYSTEMS; FEMALE; GREAT BRITAIN; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; PAIN; PILOT PROJECTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 79957616688     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2010.551676     Document Type: Article

References (23)

1. National Institute for Health and Clinical Excellence. (2008) [online]. Available from: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008pdf. Accessed 23 July 2010 .
2. Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981;56: 516-20 (Pubitemid 11023593)
3. Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics 2008;5(1):114-22 (Pubitemid 350299303)
4. Deer T, Winkelmü ller W, Erdine S, Bedder M, Burchiel K. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation 1999; 2:55-66 (Pubitemid 29268513)
5. Mueller-Schwefe G, Hassenbusch SJ, Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation 1999; 2(2):77-87
6. Raphael JH, Gnanadurai TV, Southall JL, Mutagi H, Kapur S. Placebo-controlled single blind study of short-term efficacy of spinal morphine in chronic non-malignant pain. Reg Anesth Pain Med 2006;31(5):47
7. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262(20):2879-86 (Pubitemid 20002550)
8. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: longterm benefits and efficacy. Surg Neurol 2001;55(2):79-88
9. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg 2002;97(4):803-10 (Pubitemid 35222400)
10. Paice JA, Winkelmü ller W, Burchiel K, Racz GB, Prager JP. Clinical realities and economic considerations: efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997;14(3 Suppl):S14-S26 (Pubitemid 27377604)
11. de Lissovoy G, Brown RE, Halpern M, Hassenbusch SJ, Ross E. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Ther 1997;19:96-112 (Pubitemid 27186442)
12. Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK. Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997;14:S36-S48 (Pubitemid 27377606)
13. Joint Formulary Committee. British National Formulary. 57th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009
14. The Euroqol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-209
15. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200 (Pubitemid 30224273)
16. Simpson BJ, Middleton P, Maddern G. Implantable spinal infusion devices for chronic pain and spasticity: an accelerated systematic review. ASERNIP-S Report No. 42 Adelaide, South Australia: ASERNIP-S, 2003
17. Phillips C. 2009 [online]. Available from: www.whatisseries.co.uk/whatis/ pdfs/What-is-a-QALY.pdf. Accessed 30 July 2010.
18. Winkelmü ller M, Winkelmü ller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996;85(3):458-67 (Pubitemid 26278029)
19. Raphael JH, Southall JL, Gnanadurai TV, Treharne GJ, Kitas GD. Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Musculoskel Dis 2002;3: 17
20. Paice JA, Penn RD, Shott S. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996;11(2):71-80 (Pubitemid 26073492)
21. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44(2):289-300
22. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336(7651):999-1003 (Pubitemid 351656091)
23. Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician 2009;12(2):345-360